Cargando…
Tripterygium wilfordii Glycosides Upregulate the New Anti-Inflammatory Cytokine IL-37 through ERK1/2 and p38 MAPK Signal Pathways
As a Chinese traditional patent medicine, Tripterygium wilfordii glycosides (TWG) have been approved by the China State Food and Drug Administration (Z32021007) for autoimmune and inflammatory diseases. Application of TWG leads to significant decrease of the inflammatory cytokines, such as IL-6, IL-...
Autores principales: | Wang, Sen, Li, Rumeng, He, Suhui, He, Lingge, Zhao, Hang, Deng, Xiaohong, Chen, Zhangquan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748296/ https://www.ncbi.nlm.nih.gov/pubmed/29403538 http://dx.doi.org/10.1155/2017/9148523 |
Ejemplares similares
-
Clinical Practice Guideline for Tripterygium Glycosides/Tripterygium wilfordii Tablets in the Treatment of Rheumatoid Arthritis
por: Lin, Na, et al.
Publicado: (2021) -
Tripterygium wilfordii glycosides ameliorates collagen-induced arthritis and aberrant lipid metabolism in rats
por: Zhu, Yitian, et al.
Publicado: (2022) -
Preparation and Characterization of Tripterygium wilfordii Multi-Glycoside Nanoparticle Using Supercritical Anti-Solvent Process
por: Chen, Fengli, et al.
Publicado: (2014) -
Beneficial Modulation of Lipid Mediator Biosynthesis in Innate Immune Cells by Antirheumatic Tripterygium wilfordii Glycosides
por: Zhang, Kehong, et al.
Publicado: (2021) -
The genome of Tripterygium wilfordii and characterization of the celastrol biosynthesis pathway
por: Pei, Tianlin, et al.
Publicado: (2021)